Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ t cell responses

S. Stager, J. Alexander, A.C. Kirby, M. Botto, N. Van Rooijen, D.F. Smith, F. Brombacher, P.M. Kaye

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

CD8+ T cells are essential for long-term, vaccine-induced resistance against intracellular pathogens. Here we show that natural antibodies, acting in concert with complement, are endogenous adjuvants for the generation of protective CD8+ T cells after vaccination against visceral leishmaniasis. IL-4 was crucial for the priming of vaccine-specific CD8+ T cells, and we defined the primary source of IL-4 as a CD11b+CD11clo phagocyte. IL-4 secretion was not observed in antibody-deficient mice and could be reconstituted with serum from normal, but not Btk immune-deficient, mice. Similarly, no IL-4 response or CD8+ T-cell priming was seen in C1qa-/- mice. These results identify a new pathway by which immune complex–mediated complement activation can regulate T-cell-mediated immunity. We propose that this function of natural antibodies could be exploited when developing new vaccines for infectious diseases.
LanguageEnglish
Pages1287-1292
Number of pages6
JournalNature Medicine
Volume9
DOIs
Publication statusPublished - 2003

Fingerprint

T-cells
Vaccines
Interleukin-4
T-Lymphocytes
Antibodies
Visceral Leishmaniasis
Complement Activation
Pathogens
Phagocytes
Antigen-Antibody Complex
Cellular Immunity
Communicable Diseases
Vaccination
Chemical activation
Serum

Keywords

  • t cell responses
  • vaccine-induced CD8+
  • endogenous adjuvants

Cite this

Stager, S., Alexander, J., Kirby, A. C., Botto, M., Van Rooijen, N., Smith, D. F., ... Kaye, P. M. (2003). Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ t cell responses. Nature Medicine, 9, 1287-1292. https://doi.org/10.1038/nm933
Stager, S. ; Alexander, J. ; Kirby, A.C. ; Botto, M. ; Van Rooijen, N. ; Smith, D.F. ; Brombacher, F. ; Kaye, P.M. / Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ t cell responses. In: Nature Medicine. 2003 ; Vol. 9. pp. 1287-1292.
@article{648e48cabde846ea802efea091b58378,
title = "Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ t cell responses",
abstract = "CD8+ T cells are essential for long-term, vaccine-induced resistance against intracellular pathogens. Here we show that natural antibodies, acting in concert with complement, are endogenous adjuvants for the generation of protective CD8+ T cells after vaccination against visceral leishmaniasis. IL-4 was crucial for the priming of vaccine-specific CD8+ T cells, and we defined the primary source of IL-4 as a CD11b+CD11clo phagocyte. IL-4 secretion was not observed in antibody-deficient mice and could be reconstituted with serum from normal, but not Btk immune-deficient, mice. Similarly, no IL-4 response or CD8+ T-cell priming was seen in C1qa-/- mice. These results identify a new pathway by which immune complex–mediated complement activation can regulate T-cell-mediated immunity. We propose that this function of natural antibodies could be exploited when developing new vaccines for infectious diseases.",
keywords = "t cell responses , vaccine-induced CD8+ , endogenous adjuvants",
author = "S. Stager and J. Alexander and A.C. Kirby and M. Botto and {Van Rooijen}, N. and D.F. Smith and F. Brombacher and P.M. Kaye",
year = "2003",
doi = "10.1038/nm933",
language = "English",
volume = "9",
pages = "1287--1292",
journal = "Nature Medicine",
issn = "1078-8956",

}

Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ t cell responses. / Stager, S.; Alexander, J.; Kirby, A.C.; Botto, M.; Van Rooijen, N.; Smith, D.F.; Brombacher, F.; Kaye, P.M.

In: Nature Medicine, Vol. 9, 2003, p. 1287-1292.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ t cell responses

AU - Stager, S.

AU - Alexander, J.

AU - Kirby, A.C.

AU - Botto, M.

AU - Van Rooijen, N.

AU - Smith, D.F.

AU - Brombacher, F.

AU - Kaye, P.M.

PY - 2003

Y1 - 2003

N2 - CD8+ T cells are essential for long-term, vaccine-induced resistance against intracellular pathogens. Here we show that natural antibodies, acting in concert with complement, are endogenous adjuvants for the generation of protective CD8+ T cells after vaccination against visceral leishmaniasis. IL-4 was crucial for the priming of vaccine-specific CD8+ T cells, and we defined the primary source of IL-4 as a CD11b+CD11clo phagocyte. IL-4 secretion was not observed in antibody-deficient mice and could be reconstituted with serum from normal, but not Btk immune-deficient, mice. Similarly, no IL-4 response or CD8+ T-cell priming was seen in C1qa-/- mice. These results identify a new pathway by which immune complex–mediated complement activation can regulate T-cell-mediated immunity. We propose that this function of natural antibodies could be exploited when developing new vaccines for infectious diseases.

AB - CD8+ T cells are essential for long-term, vaccine-induced resistance against intracellular pathogens. Here we show that natural antibodies, acting in concert with complement, are endogenous adjuvants for the generation of protective CD8+ T cells after vaccination against visceral leishmaniasis. IL-4 was crucial for the priming of vaccine-specific CD8+ T cells, and we defined the primary source of IL-4 as a CD11b+CD11clo phagocyte. IL-4 secretion was not observed in antibody-deficient mice and could be reconstituted with serum from normal, but not Btk immune-deficient, mice. Similarly, no IL-4 response or CD8+ T-cell priming was seen in C1qa-/- mice. These results identify a new pathway by which immune complex–mediated complement activation can regulate T-cell-mediated immunity. We propose that this function of natural antibodies could be exploited when developing new vaccines for infectious diseases.

KW - t cell responses

KW - vaccine-induced CD8+

KW - endogenous adjuvants

U2 - 10.1038/nm933

DO - 10.1038/nm933

M3 - Article

VL - 9

SP - 1287

EP - 1292

JO - Nature Medicine

T2 - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

ER -